We explored the efficacy of the IGEV regimen (ifosfamide, gemcitabine, vinorelbine and prednisone) combined with a fixed dose of lenograstim ( 263 mu g/day) to mobilize peripheral blood stem cells (PBSCs) in 90 Hodgkin's lymphoma patients. The median total CD34+ cells/mu l peak, colony-forming units granulocyte-macrophage and white blood cells for all individual collection sets were 85/mu l, 12 x 10(4)/kg and 20 700/mu l, respectively. An adequate number of CD34+ cells ( more than 3 x 10(6) or 6 x 10(6) CD34+ cells/kg depending on whether single or tandem high-dose chemotherapy was used) were collected in 89 out of 90 (98.7%) mobilized patients, whereas the only failure reached 2.3 x 10(6) CD34+ cells/kg. The median CD34+ cell collections were 11 x 10(6)/kg ( range 2.3 39 x 10(6)/kg) and 10 x 10(6)/kg ( range 6-22.0 x 10(6)/kg) with a median of 1 and 2 leukaphereses for patients eligible for single high-dose treatment and for candidates for tandem transplant, respectively. Target yields were reached in 71.43 and 49.09% and additionally in 17.14 and 43.64% of cases after the first and second apheresis procedures, respectively. Hematological and non-hematological side effects were acceptable, and no toxic deaths occurred. Thirty-four patients received a single and 47 received tandem transplantation with rapid engraftment. These results confirm that the IGEV regimen with lenograstim support can be used successfully and safely to mobilize PBSCs.
|Titolo:||IGEV regimen and a xed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients|
|Data di pubblicazione:||2007|
|Appare nelle tipologie:||1.1 Articolo in rivista|